STOCK TITAN

IO Biotech, Inc. - IOBT STOCK NEWS

Welcome to our dedicated page for IO Biotech news (Ticker: IOBT), a resource for investors and traders seeking the latest updates and insights on IO Biotech stock.

IO Biotech, Inc. (IOBT) is a clinical-stage biopharmaceutical company dedicated to developing innovative immune therapies for treating cancer. Their focus is on creating first-in-class immune-modulating anti-cancer treatments based on a groundbreaking platform technology. This platform enables the activation of T cells that specifically target immune inhibitory molecules.

IO Biotech has a robust pipeline featuring two leading immune-modulating therapies, IDO and PD-L1, which are currently in clinical development. Additionally, several other compounds are nearing the end of the preclinical phase. The company's proven track record in advancing compounds to the clinical stage underscores their expertise and commitment to innovation in cancer treatment.

The company's product candidates utilize the T-win technology platform, designed to trigger the immune system to attack and disrupt multiple pathways that regulate tumor-induced immunosuppression. This unique approach aims to enhance the body's natural ability to fight cancer, offering a promising avenue for patients battling this disease.

With an experienced management team and a world-class advisory board, IO Biotech is well-positioned in the field of immuno-oncology. Recent achievements include the advancement of their pivotal Phase 3 Clinical Trial (IOB-013/KN-D18) and significant progress with their drugs IO102 and IO103. The company’s dedication to cutting-edge research and development is evident through their continuous efforts in preclinical and clinical trials.

For the latest updates and detailed information about IO Biotech, their therapies, ongoing projects, and financial condition, visit their official website or contact Maryann Cimino, Director of Investor Relations, at mci@iobiotech.com.

Rhea-AI Summary
IO Biotech (Nasdaq: IOBT) appoints Heidi Hunter, a biotech leader with over 25 years of experience, to its board of directors. Priyanka Belawat, PhD, steps down. The company is advancing IO102-IO103 through a Phase 3 pivotal trial in first-line advanced melanoma, with interim readout expected in mid-2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
IO Biotech announces private placement for approximately $75 million
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.6%
Tags
none
Rhea-AI Summary
IO Biotech announces the dosing of the first patient in its investigator-initiated trial for its immune-modulating cancer vaccine in combination with pembrolizumab for non-muscle invasive bladder cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.12%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.15%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-26.48%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.85%
Tags
management
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.48%
Tags
conferences
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.91%
Tags

FAQ

What is the current stock price of IO Biotech (IOBT)?

The current stock price of IO Biotech (IOBT) is $0.771 as of December 20, 2024.

What is the market cap of IO Biotech (IOBT)?

The market cap of IO Biotech (IOBT) is approximately 49.4M.

What does IO Biotech, Inc. do?

IO Biotech, Inc. develops innovative immune therapies for the treatment of cancer, focusing on immune-modulating anti-cancer therapies.

What are IO Biotech's leading therapies?

Their leading therapies target IDO and PD-L1, both currently in clinical development.

What technology platform does IO Biotech use?

They use the T-win technology platform, which aims to induce the immune system to disrupt multiple pathways regulating tumor-induced immunosuppression.

What is the company's track record in advancing therapies?

IO Biotech has a proven track record of progressing compounds to the clinical stage.

Who is part of IO Biotech's team?

They have an experienced management team in immuno-oncology and a world-class advisory board.

What recent achievements has IO Biotech made?

Recent achievements include the advancement of pivotal Phase 3 Clinical Trials and progress with drugs IO102 and IO103.

How can I get the latest updates on IO Biotech?

You can visit their official website or contact their Director of Investor Relations, Maryann Cimino, at mci@iobiotech.com.

What is the focus of IO Biotech's research?

Their research focuses on developing first-in-class immune-modulating cancer vaccines.

What is unique about IO Biotech's approach to cancer treatment?

Their unique approach involves activating T cells to specifically target immune inhibitory molecules, enhancing the body's ability to fight cancer.

How can I contact IO Biotech for more information?

You can contact Maryann Cimino, Director of Investor Relations, at 617-710-7305 or via email at mci@iobiotech.com.

IO Biotech, Inc.

Nasdaq:IOBT

IOBT Rankings

IOBT Stock Data

49.41M
65.73M
0.24%
76.79%
0.31%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
COPENHAGEN